Adolescent girls and young women in Zambia chose long-acting injectable pre-exposure prophylaxis based on five primary facilitating factors, according to a qualitative study published in AIDS Research and Therapy. The investigation found that uptake of the injectable formulation was driven by the perception that partners cannot be trusted, the discretion of injections in reducing stigma and associated discrimination, the freedom of a long-acting modality that eliminates daily pill-taking burdens, the ability of established intervention programs to counter community misinformation about new health technologies, and the role of friends in encouraging uptake through peer support. Together, these five themes explained how young women in a community setting navigated real-world decisions regarding biomedical HIV prevention.
The research addressed an ongoing challenge in HIV prevention across eastern and southern Africa, where adolescent girls and young women face a disproportionate risk of HIV acquisition. Although daily oral pre-exposure prophylaxis is effective for HIV prevention, uptake of daily oral PrEP among this population has remained inadequate. Prior research examining hypothetical preferences had suggested that long-acting injectable PrEP would be preferred to oral PrEP by young women. However, little was known about the real-world implementation of long-acting injectable PrEP. Because Zambia was one of the first countries to integrate cabotegravir long-acting injectable PrEP into its national guidelines, the country offered an early opportunity to explore how these prevention options function in community practice.
To investigate the factors influencing uptake of cabotegravir injectable PrEP among adolescent girls and young women in a community setting, the researchers conducted a qualitative study informed by Andersen’s Behavioral Model of Health Service Use. In late 2024, the investigators conducted semi-structured interviews with 33 adolescent girls and young women aged 16 to 24 years. The participants were recruited from two community-based centers associated with the Determined, Resilient, Empowered, AIDS-free, Mentored and Safe initiative, known as DREAMS, located in Southern Province, Zambia.
The interviews revealed that interpersonal dynamics and partner mistrust formed a central reason for choosing the injectable intervention. Within social environments characterized by unequal gender power dynamics, cabotegravir injectable PrEP enabled young women to maintain sexual health autonomy.
A second major set of findings centered on how the injectable format resolved significant practical and social obstacles that historically limited oral PrEP uptake. Participants indicated that cabotegravir addressed barriers related to oral PrEP including stigma, disclosure, and cognitive burden. Furthermore, participants emphasized that the freedom of a long-acting modality eliminated the burdens of daily pill taking. By removing the need to remember and ingest a daily tablet, the injectable option relieved young women of the constant cognitive burden associated with oral adherence.
Community institutions and peer networks were also instrumental in supporting the uptake of cabotegravir injectable PrEP. The study highlighted that established intervention programs played a critical role in countering community misinformation concerning new health technologies. Specifically, the DREAMS program’s established community trust proved essential for overcoming misinformation in the surrounding community and facilitating participants’ uptake of the injectable method.
In concluding their study, the authors emphasized that long-acting injectable cabotegravir provided adolescent girls and young women with a practical means to maintain sexual health autonomy within contexts of unequal gender power dynamics. By eliminating the daily cognitive burdens of pill adherence and offering discreet protection that reduces stigma and disclosure risks, the long-acting injectable formulation addressed the primary barriers that have historically curtailed oral PrEP uptake. The study’s scope was defined by qualitative semi-structured interviews with 33 adolescent girls and young women aged 16 to 24 attending two DREAMS centers in Southern Province, Zambia, reflecting real-world implementation insights gathered during late 2024.
Subject of Research: Factors influencing long-acting injectable PrEP uptake among adolescent girls and young women in Zambia
Article Title: “My heart is at peace because I know that I am protected:” understanding the factors that facilitate adolescent girls and young women’s uptake of long-acting injectable PrEP in Zambia
Article References: Stoebenau, K., Mwale, M., Muchanga, G., McDonald, K., Geaty, C., K. Mwango, L., Baumhart, C., Blanco, N., Chilyabanyama, O. N., Nalungwe, K., Maambo, C., Mulenga, L., Claassen, C. W., & Lavoie, M.-C. (2026). “My heart is at peace because I know that I am protected:” understanding the factors that facilitate adolescent girls and young women’s uptake of long-acting injectable PrEP in Zambia. AIDS Research and Therapy. https://doi.org/10.1186/s12981-026-00914-0
Image Credits: AI Generated
DOI: 10.1186/s12981-026-00914-0
Keywords: HIV prevention, LAI-PrEP, Zambia, Adolescent girls, Young women, Qualitative study, DREAMS program, Cabotegravir, Health access, Stigma reduction, heart, peace
News Source: Ophelia Keating. (November 10, 2026). Zambia Study Links Trust and Discretion to PrEP Uptake. Scienmag.



